Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Gains from Investment Securities (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Gains from Investment Securities for 11 consecutive years, with $250160.0 as the latest value for Q2 2025.

  • Quarterly Gains from Investment Securities changed N/A to $250160.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $250160.0 through Jun 2025, changed N/A year-over-year, with the annual reading at $7.0 for FY2024, 98.01% down from the prior year.
  • Gains from Investment Securities hit $250160.0 in Q2 2025 for Aptevo Therapeutics, up from $2850.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $400000.0 in Q2 2022 to a low of $7.0 in Q4 2024.
  • Historically, Gains from Investment Securities has averaged $151070.9 across 5 years, with a median of $125156.5 in 2021.
  • Biggest five-year swings in Gains from Investment Securities: soared 369.93% in 2023 and later plummeted 98.01% in 2024.
  • Year by year, Gains from Investment Securities stood at $16392.0 in 2021, then surged by 2340.21% to $400000.0 in 2022, then tumbled by 99.91% to $352.0 in 2023, then tumbled by 98.01% to $7.0 in 2024, then soared by 3573614.29% to $250160.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for APVO at $250160.0 in Q2 2025, $2850.0 in Q1 2025, and $7.0 in Q4 2024.